Cargando…
Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning
BACKGROUND: The optimal number of systematic biopsy cores in the era of multi-parametric MRI targeted biopsy remains unclear, especially on its impact of focal therapy planning. Our objective is to investigate the impact of reducing the number of systematic cores on prostate cancer detection in the...
Autores principales: | Lee, Alvin Y. M., Chen, Kenneth, Tan, Yu Guang, Lee, Han Jie, Shutchaidat, Vipatsorn, Fook-Chong, Stephanie, Cheng, Christopher W. S., Ho, Henry S. S., Yuen, John S. P., Ngo, Nye Thane, Law, Yan Mee, Tay, Kae Jack |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705237/ https://www.ncbi.nlm.nih.gov/pubmed/35027690 http://dx.doi.org/10.1038/s41391-021-00485-3 |
Ejemplares similares
-
Correction: Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning
por: Lee, Alvin Y. M., et al.
Publicado: (2022) -
Surveillance one year post focal cryotherapy for clinically significant prostate cancer using mpMRI and PIRADS v2.1: An initial experience from a prospective phase II mandatory biopsy study
por: Velaga, Jyothirmayi, et al.
Publicado: (2023) -
Defining prostate cancer size and treatment margin for focal therapy: does intralesional heterogeneity impact the performance of multiparametric MRI?
por: Aslim, Edwin Jonathan, et al.
Publicado: (2021) -
Outcomes of combination MRI-targeted and transperineal template biopsy in restaging low-risk prostate cancer for active surveillance
por: Chen, Kenneth, et al.
Publicado: (2018) -
What is the ideal number of biopsy cores per lesion in targeted prostate biopsy?
por: Sonmez, Gokhan, et al.
Publicado: (2020)